T0	InappropriateFollowUpDuration 15987 16073	did not call patients back for study visits for detailed assessment of quality of life
T1	ResponsivenessOfMeasurement 16220 16269	chose poor outcome as our primary outcome measure
T2	OutcomeMeasures 16362 16429	did not include delayed cerebral haemorrhage as a secondary outcome
T3	OutcomeMeasures 16455 16498	did not include other baseline measurements
T4	AnnotatorNotes T13	No appropriate outcome measuring method
T5	AnnotatorNotes T12	No appropriate outcome measuring method
T6	OTHER 16611 16679	do not have complete information about adherence to study medication
T7	OTHER 16684 16747	did not require magnesium concentration to be routinely checked
T8	AnnotatorNotes T15	In appropriate study implementation
T9	Blinding 16834 16875	possibility of unmasking of investigators
T10	AnnotatorNotes T16	Blinding Investigator
T11	LackOfOutcomeMeasurementData 17071 17233	effect of magnesium treatment on cognitive symptoms—which are common after aneurysmal subarachnoid haemorrhage—might have been missed by the modified Rankin Scale
T12	OTHER 18088 18163	time to treatment with magnesium in MASH 2 might not have been short enough
T13	AnnotatorNotes T18	Not adequate treatment time
T14	InappropriateFollowUpDuration 17371 17404	a benefit might be detected later
